ABSTRACT

A subject of the invention is a product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent for a therapeutic use which is simultaneous, separate or spread over time in the treatment of cancer.

- According to the invention, the other anti-cancer agent is preferably chosen from:
 - analogues of DNA bases such as 5-fluorouracil;
 - Type I and/or II topoisomerase inhibitors such as for example camptothecin and its analogues, doxorubicin or amsacrine;
 - compounds interacting with the cell spindle such as for example paclitaxel (Taxol);
- 10 compounds acting on the cytoskeleton such as vinblastine;
 - inhibitors of the transduction of the signal passing through the heterotrimeric G proteins;
 - prenyltransferase inhibitors, and in particular farnesyltransferase inhibitors;
 - cyclin-dependent kinase (CDKs) inhibitors;
- 15 alkylating agents such as cisplatin;
 - antagonists of folic acid such as methotrexate; and
 - inhibitors of the synthesis of DNA and cell division cell such as mitomycin C.
 - A further subject of the invention is $(1R)-1-[(\{(2R)-2-a\min_{3-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]-$
- 3-oxopropyl}dithio)methyl]-2-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]-2-oxoethylamine, or a pharmaceutically acceptable salt thereof, useful as an anticancer agent.